515 related articles for article (PubMed ID: 36568085)
1. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
2. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
3. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
4. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort.
Aldhaleei WA; Abegaz TM; Bhagavathula AS
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399414
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
Ruggiero R; Mascolo A; Spezzaferri A; Carpentieri C; Torella D; Sportiello L; Rossi F; Paolisso G; Capuano A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399362
[TBL] [Abstract][Full Text] [Related]
8. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
Trujillo J
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
[TBL] [Abstract][Full Text] [Related]
10. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
11. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
[TBL] [Abstract][Full Text] [Related]
12. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
13. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
Lingvay I; Hansen T; Macura S; Marre M; Nauck MA; de la Rosa R; Woo V; Yildirim E; Wilding J
BMJ Open Diabetes Res Care; 2020 Oct; 8(2):. PubMed ID: 33115821
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
Rayner CK; Wu T; Aroda VR; Whittington C; Kanters S; Guyot P; Shaunik A; Horowitz M
Diabetes Obes Metab; 2021 Jan; 23(1):136-146. PubMed ID: 32991041
[TBL] [Abstract][Full Text] [Related]
16. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
Zhang Z; Zhang Q; Tan Y; Chen Y; Zhou X; Liu S; Yu J
Front Endocrinol (Lausanne); 2023; 14():1149328. PubMed ID: 37484944
[TBL] [Abstract][Full Text] [Related]
17. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
18. Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Shirani A; Cross AH; Stuve O
Ther Adv Neurol Disord; 2024; 17():17562864241241383. PubMed ID: 38566910
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Madsbad S; Holst JJ
Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
[TBL] [Abstract][Full Text] [Related]
20. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]